Providers are required to obtain a recent baseline brain MRI prior to initiating treatment and individuals also must undergo scans prior to the second, third, fourth and seventh infusions. 
 

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

The Australian radiopharma firm's financial maneuver comes amid its roll out of the first targeted positron emission tomography agent for kidney cancer. 

Demand is growing for the modality, but provider groups, particularly those in private practice, have struggled to meet state regulatory requirements. 

The Indianapolis-based drugmaker can hit the hefty total by reaching certain clinical, regulatory and commercial milestones.

The FIND Act is supported by several industry stakeholders including ACR and the Society of Nuclear Medicine & Molecular Imaging. 

Comparing only imaging centers that operated both quarters, MRI volumes increased 10% compared to Q1 of 2023 while PET/CT was up more than 15%. 

The original inciting incident occurred in July 2014, when 58-year-old James Griswold visited the Connecticut provider group for a nuclear stress imaging test.